PsychedelicNewsBreaks – Skinvisible Pharmaceuticals, Inc. (SKVI) Could Have the Solution to the Flu Epidemic

Skinvisible Pharmaceuticals (OTCQB: SKVI) is a topical and transdermal product development company with a proprietary drug delivery system, Invisicare, that improves how ingredients are delivered to and through the skin including the medicinal components of marijuana; specifically, CBD (cannabidiol) and the psychoactive marijuana ingredient THC (tetrahydrocannabinol). The key to Skinvisible’s patented technology and trademarked Invisicare family of polymer delivery vehicles is its formula and process for combining hydrophilic and hydrophobic polymers into stable complexes in water emulsions. Applications of this novel technology are discussed in a recent article that says in part, “H7N9 (a type of avian influenza virus) could be the one to cause the next global flu pandemic, the World Health Organization (WHO) warns (http://cnw.fm/MXEb0). Luckily, the flu prophylactic market is already offering some adequate options, and DermSafe® by Skinvisible, Inc. (OTCQB: SKVI) subsidiary Skinvisible Pharmaceuticals, Inc. is one of them. In June, Skinvisible announced the first international sale of DermSafe in China – a country that’s known to have the first reported cases of human avian influenza infections.”

To view the full article, visit http://cnw.fm/2iCFM

About Skinvisible Pharmaceuticals, Inc.

Skinvisible Pharmaceuticals is a research and development company that licenses its proprietary formulations made with Invisicare®, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time, allowing for the controlled release of actives. For more information, visit the company’s website at www.Skinvisible.com

More from PsychedelicNewsBreaks

• PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference
• PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Re-files ANDA for Preservative-Free IV Ketamine KETAFREE(TM)
• PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives FDA Approval of Suitability Petition for Preservative-Free Ketamine Product

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) PsychedelicNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. PNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled visibility, recognition and brand awareness. PNW is where news, content and information converge.

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/disclaimer/

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com